245 related articles for article (PubMed ID: 31454075)
1. Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience.
Vernieri F; Paolucci M; Altamura C; Pasqualetti P; Mastrangelo V; Pierangeli G; Cevoli S; D'Amico D; Grazzi L
Headache; 2019 Sep; 59(8):1300-1309. PubMed ID: 31454075
[TBL] [Abstract][Full Text] [Related]
2. Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers.
Tassorelli C; Aguggia M; De Tommaso M; Geppetti P; Grazzi L; Pini LA; Sarchielli P; Tedeschi G; Martelletti P; Cortelli P
J Headache Pain; 2017 Dec; 18(1):66. PubMed ID: 28667550
[TBL] [Abstract][Full Text] [Related]
3. Effects of Botulinum Toxin A on Allodynia in Chronic Migraine: An Observational Open-Label Two-Year Study.
de Tommaso M; Brighina F; Delussi M
Eur Neurol; 2019; 81(1-2):37-46. PubMed ID: 31013496
[TBL] [Abstract][Full Text] [Related]
4. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
Santoro A; Fontana A; Miscio AM; Zarrelli MM; Copetti M; Leone MA
Neurol Sci; 2017 Oct; 38(10):1779-1789. PubMed ID: 28726049
[TBL] [Abstract][Full Text] [Related]
5. Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data.
Ornello R; Guerzoni S; Baraldi C; Evangelista L; Frattale I; Marini C; Tiseo C; Pistoia F; Sacco S
J Headache Pain; 2020 Apr; 21(1):40. PubMed ID: 32334534
[TBL] [Abstract][Full Text] [Related]
6. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
[TBL] [Abstract][Full Text] [Related]
7. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.
Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Mitsikostas DD
J Headache Pain; 2016 Dec; 17(1):84. PubMed ID: 27640152
[TBL] [Abstract][Full Text] [Related]
8. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
[TBL] [Abstract][Full Text] [Related]
9. Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
Ruscheweyh R; Athwal B; Gryglas-Dworak A; Frattale I; Latysheva N; Ornello R; Pozo-Rosich P; Sacco S; Torres Ferrus M; Stark CD
Headache; 2020 Sep; 60(8):1673-1682. PubMed ID: 32797631
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin injection in the management of chronic migraine: the Saudi experience with a proposal for a new protocol.
Algahtani H; Shirah B; Sukkar G; Bukhari H; Meftah I; Alhazmi A; Alshareef A; Algethami A; Alshanqiti A; Andeejani M
Acta Neurol Belg; 2021 Dec; 121(6):1783-1787. PubMed ID: 33058053
[TBL] [Abstract][Full Text] [Related]
11. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
[TBL] [Abstract][Full Text] [Related]
12. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
Aicua-Rapun I; Martínez-Velasco E; Rojo A; Hernando A; Ruiz M; Carreres A; Porqueres E; Herrero S; Iglesias F; Guerrero AL
J Headache Pain; 2016 Dec; 17(1):112. PubMed ID: 27957623
[TBL] [Abstract][Full Text] [Related]
13. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
Vernieri F; Altamura C; Brunelli N; Costa CM; Aurilia C; Egeo G; Fofi L; Favoni V; Pierangeli G; Lovati C; Aguggia M; d'Onofrio F; Doretti A; Di Fiore P; Finocchi C; Rao R; Bono F; Ranieri A; Albanese M; Cevoli S; Barbanti P;
J Headache Pain; 2021 May; 22(1):35. PubMed ID: 33941080
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: A clinic-based prospective study.
Lee MJ; Lee C; Choi H; Chung CS
J Neurol Sci; 2016 Apr; 363():51-4. PubMed ID: 27000220
[TBL] [Abstract][Full Text] [Related]
15. [Botulinum toxin injections for chronic migraine in adolescents - an early therapeutic option in the transition from neuropaediatrics to neurology].
Bernhard MK; Bertsche A; Syrbe S; Weise S; Merkenschlager A
Fortschr Neurol Psychiatr; 2014 Jan; 82(1):39-42. PubMed ID: 24446117
[TBL] [Abstract][Full Text] [Related]
16. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial.
Suzuki K; Iizuka T; Sakai F
Intern Med; 2007; 46(13):959-63. PubMed ID: 17603233
[TBL] [Abstract][Full Text] [Related]
18. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life.
Tassorelli C; Tedeschi G; Sarchielli P; Pini LA; Grazzi L; Geppetti P; De Tommaso M; Aguggia M; Cortelli P; Martelletti P
Expert Rev Neurother; 2018 Feb; 18(2):167-176. PubMed ID: 29280408
[TBL] [Abstract][Full Text] [Related]
20. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study.
Domínguez C; Vieites-Prado A; Pérez-Mato M; Sobrino T; Rodríguez-Osorio X; López A; Campos F; Martínez F; Castillo J; Leira R
Headache; 2018 Jan; 58(1):78-87. PubMed ID: 29131327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
